1. 1.‎ Li L, Vlisides PE. Ketamine: 50 Years of Modulating the Mind. Front Hum Neurosci. 2016;10:612.‎ ‎2.‎ F. Aroni, N. Iacovidou, I. Dontas, C. Pourzitaki, and T. Xanthos, “Pharmacological aspects and potential ‎new clinical applications of ketamine: reevaluation of an old drug,” Journal of Clinical Pharmacology, ‎vol. 49, no. 8, pp. 957–964, 2009.‎ ‎3.‎ J. Persson, “Ketamine in pain management,” CNS Neuroscience & Therapeutics, vol. 19, no. 6, pp. ‎‎396–402, 2013.‎ ‎4.‎ Liao Y, Tang YL, Hao W. Ketamine and international regulations. Am J Drug Alcohol Abuse. 2017 ‎Sep;43(5):495-504.‎ ‎5.‎ Cartwright PD, Pingel SM. Midazolam and diazepam in ketamine anaesthesia. Anaesthesia. 1984 ‎May;39(5):439-42. ‎ ‎6.‎ Andrade C. Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse ‎Effects, and Mechanism of Action. J Clin Psychiatry. 2017 Apr;78(4):e415-e419.‎ ‎7.‎ M. Naughton, G. Clarke, O. F. O'Leary, J. F. Cryan, and T. G. Dinan, “A review of ketamine in affective ‎disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed ‎mechanisms of action,” Journal of Affective Disorders, vol. 156, pp. 24–35, 2014.‎ ‎8.‎ P. Azari, D. R. Lindsay, D. Briones, C. Clarke, T. Buchheit, and S. Pyati, “Efficacy and safety of ketamine ‎in patients with complex regional pain syndrome: a systematic review,” CNS Drugs, vol. 26, no. 3, pp. ‎‎215–228, 2012.‎ ‎9.‎ R. F. Bell, C. Eccleston, and E. A. Kalso, “Ketamine as an adjuvant to opioids for cancer pain,” The ‎Cochrane Database of Systematic Reviews, no. 11, Article ID CD003351, 2012.‎ ‎10.‎ J. H. Krystal, S. Madonick, E. Perry et al., “Potentiation of low dose ketamine effects by naltrexone: ‎potential implications for the pharmacotherapy of alcoholism,” Neuropsychopharmacology, vol. 31, no. ‎‎8, pp. 1793–1800, 2006. ‎ ‎11.‎ E. Krupitsky, A. Burakov, T. Romanova, I. Dunaevsky, R. Strassman, and A. Grinenko, “Ketamine ‎psychotherapy for heroin addiction: immediate effects and two-year follow-up,” Journal of Substance ‎Abuse Treatment, vol. 23, no. 4, pp. 273–283, 2002.‎ ‎12.‎ K. R. Jat and D. Chawla, “Ketamine for management of acute exacerbations of asthma in children,” The ‎Cochrane Database of Systematic Reviews, vol. 11, Article ID CD009293, 2012.‎ ‎13.‎ K. R. Jat, C. Azad, and V. Guglani, “Use of ketamine for refractory wheezing in an infant,” Indian ‎Pediatrics, vol. 49, no. 7, pp. 587–588, 2012.‎ ‎14.‎ M. Wang, Q. Wang, Y. Y. Yu, and W. S. Wang, “An effective dose of ketamine for eliminating pain ‎during injection of propofol: a dose response study,” Annales Francaises d'Anesthesie et de ‎Reanimation, vol. 32, no. 9, pp. e103–e106, 2013.‎ ‎15.‎ N. Katalinic, R. Lai, A. Somogyi, P. B. Mitchell, P. Glue, and C. K. Loo, “Ketamine as a new treatment for ‎depression: a review of its efficacy and adverse effects,” The Australian and New Zealand Journal of ‎Psychiatry, vol. 47, no. 8, pp. 710–727, 2013.‎ ‎16.‎ Passie T, Adams HA, Logemann F, Brandt SD, Wiese B, Karst M. Comparative effects of (S)-ketamine ‎and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive ‎performance in healthy volunteers. European Neuropsychopharmacology. 2021 Mar 1;44:92-104.‎ ‎17.‎ Domino EF. Neuronal mechanisms of ketamine-induced anesthesia. International journal of ‎neuropharmacology. 1968 Nov 1;7(6):557-73.‎ ‎18.‎ Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-‎methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992 Mar;260(3):1209-13.‎ ‎19.‎ Ben-Shlomo I, Rosenbaum A, Hadash O, Katz Y. Intravenous midazolam significantly enhances the ‎lethal effect of thiopental but not that of ketamine in mice. Pharmacol Res. 2001 Dec;44(6):509-12. ‎ ‎20.‎ Hansen G, Jensen SB, Chandresh L, Hilden T. The psychotropic effect of ketamine. J Psychoactive ‎Drugs. 1988 Oct-Dec;20(4):419-25. ‎ ‎21.‎ Deer TR, Pope JE, Hayek SM, Lamer TJ, Veizi IE, Erdek M, Wallace MS, Grider JS, Levy RM, Prager J, ‎Rosen SM, Saulino M, Yaksh TL, De Andrés JA, Abejon Gonzalez D, Vesper J, Schu S, Simpson B, ‎Mekhail N. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug ‎Delivery: Guidance for Improving Safety and Mitigating Risks. Neuromodulation. 2017 Feb;20(2):155-‎‎176.‎ ‎22.‎ C. J. A. Morgan and H. V. Curran, “Ketamine use: a review,” Addiction, vol. 107, no. 1, pp. 27–38, 2012. ‎ ‎23.‎ R. J. Strayer and L. S. Nelson, “Adverse events associated with ketamine for procedural sedation in ‎adults,” The American journal of emergency medicine, vol. 26, no. 9, pp. 985–1028, 2008.‎ ‎24.‎ P. Azari, D. R. Lindsay, D. Briones, C. Clarke, T. Buchheit, and S. Pyati, “Efficacy and safety of ketamine ‎in patients with complex regional pain syndrome: a systematic review,” CNS Drugs, vol. 26, no. 3, pp. ‎‎215–228, 2012.‎ ‎25.‎ N. Katalinic, R. Lai, A. Somogyi, P. B. Mitchell, P. Glue, and C. K. Loo, “Ketamine as a new treatment for ‎depression: a review of its efficacy and adverse effects,” The Australian and New Zealand Journal of ‎Psychiatry, vol. 47, no. 8, pp. 710–727, 2013.‎ ‎26.‎ S. Himmelseher and M. E. Durieux, “Ketamine for perioperative pain management,” Anesthesiology, vol. ‎‎102, no. 1, pp. 211–220, 2005.‎ ‎27.‎ H. S. Smith, “Ketamine-induced urologic insult (KIUI),” Pain Physician, vol. 13, no. 6, pp. E343–E346, ‎‎2010.‎ ‎28.‎ A. C. Scallet, L. C. Schmued, W. Slikker Jr. et al., “Developmental neurotoxicity of ketamine: ‎morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic ‎neurons,” Toxicological Sciences, vol. 81, no. 2, pp. 364–370, 2004.‎ ‎29.‎ V. Jevtovic-Todorovic, D. F. Wozniak, N. D. Benshoff, and J. W. Olney, “A comparative evaluation of the ‎neurotoxic properties of ketamine and nitrous oxide,” Brain Research, vol. 895, no. 1-2, pp. 264–267, ‎‎2001.‎ ‎30.‎ C. Dong and K. J. S. Anand, “Developmental neurotoxicity of ketamine in pediatric clinical use,” ‎Toxicology Letters, vol. 220, no. 1, pp. 53–60, 2013.‎ ‎31.‎ M. G. Paule, M. Li, R. R. Allen et al., “Ketamine anesthesia during the first week of life can cause long-‎lasting cognitive deficits in rhesus monkeys,” Neurotoxicology and Teratology, vol. 33, no. 2, pp. 220–‎‎230, 2011.‎ ‎32.‎ L. C. Chang, S. R. Raty, J. Ortiz, N. S. Bailard, and S. J. Mathew, “The emerging use of ketamine for ‎anesthesia and sedation in traumatic brain injuries,” CNS Neuroscience & Therapeutics, vol. 19, no. 6, ‎pp. 390–395, 2013.‎ ‎33.‎ K. Michalczyk, J. E. Sullivan, and J. W. Berkenbosch, “Pretreatment with midazolam blunts the rise in ‎intracranial pressure associated with ketamine sedation for lumbar puncture in children,” Pediatric ‎Critical Care Medicine, vol. 14, no. 3, pp. e149–e155, 2013.‎ ‎34.‎ N. Gaspard, B. Foreman, L. M. Judd et al., “Intravenous ketamine for the treatment of refractory status ‎epilepticus: a retrospective multicenter study,” Epilepsia, vol. 54, no. 8, pp. 1498–1503, 2013.‎ ‎35.‎ E. B. Perry Jr., J. A. Cramer, H.-S. Cho et al., “Psychiatric safety of ketamine in psychopharmacology ‎research,” Psychopharmacology, vol. 192, no. 2, pp. 253–260, 2007.‎ ‎36.‎ Demaria S, Weinkauf JL. Cocaine and the club drugs. Int Anesthesiol Clin. 2011 Winter;49(1):79-101. ‎ ‎37.‎ Tobias JD, Leder M. Procedural sedation: A review of sedative agents, monitoring, and management of ‎complications. Saudi J Anaesth. 2011 Oct;5(4):395-410.‎ ‎38.‎ Bokor G, Anderson PD. Ketamine: an update on its abuse. J Pharm Pract. 2014 Dec;27(6):582-6.‎ ‎39.‎ Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, Viscusi ER, Narouze S, ‎Davis FN, Ritchie EC, Lubenow TR, Hooten WM. Consensus Guidelines on the Use of Intravenous ‎Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain ‎Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. ‎Reg Anesth Pain Med. 2018 Jul;43(5):521-546.‎ ‎40.‎ Trivedi S, Kumar R, Tripathi AK, Mehta RK. A Comparative Study of Dexmedetomidine and Midazolam ‎in Reducing Delirium Caused by Ketamine. J Clin Diagn Res. 2016 Aug;10(8):UC01-4. ‎ ‎41.‎ Sollazzi L, Modesti C, Vitale F, Sacco T, Ciocchetti P, Idra AS, Tacchino RM, Perilli V. Preinductive use ‎of clonidine and ketamine improves recovery and reduces postoperative pain after bariatric surgery. ‎Surg Obes Relat Dis. 2009 Jan-Feb;5(1):67-71.‎